Sino-American biopharma Ascentage Pharma announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575 ...

Lewy body dementia (LBD) remains one of the most overlooked and complex neurodegenerative conditions, but momentum is ...

Shares in US biotech Ultragenyx Pharmaceutical (Nasdaq: RARE) and its UK-based partner Mereo BioPharma (Nasdaq: MREO) tumbled ...

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...

French biotech Osivax has published results from a Phase IIa trial showing that its lead candidate OVX836, a broad-spectrum ...

China-based biotech Biocytogen has signed a global licensing agreement with oncology-focused BeOne Medicines (SHA: 688235), ...

The US Food and Drug Administration (FDA) has accepted for review Merck & Co’s New Drug Application (NDA) for ...

The US Food and Drug Administration (FDA) has taken the radical move of publishing more than 200 decision letters, known as ...

The European Commission has approved Tevimbra (tislelizumab), alongside gemcitabine and cisplatin, for the first-line ...

US pharma major AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today ...

BeOne Medicines - the Sino-American oncology specialist formerly known as BeiGene (SHA: 688235) - has announced that the ...

US late-stage oncology-focused Revolution Medicines and Iambic Therapeutics, which is developing novel medicines using its AI ...